Cancer drug discovery faces numerous challenges. One significant issue is the heterogeneity of cancer, meaning that different types of cancer and even different tumors within the same type can behave very differently. This makes it difficult to develop a one-size-fits-all treatment. Another challenge is the development of drug resistance. Cancer cells can adapt and become resistant to treatments, necessitating the continuous development of new drugs. Additionally, the high cost and lengthy timeframes associated with drug development pose financial and logistical barriers.
